Phase 1/1b Trial of MK-1966 in Combination With SD-101 in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs MK 1966 (Primary) ; SD 101 Dynavax (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 19 Jan 2018 Status changed from active, no longer recruiting to discontinued.
- 08 Jan 2018 Planned End Date changed from 28 Dec 2018 to 8 Jan 2018.
- 08 Jan 2018 Planned primary completion date changed from 28 Dec 2018 to 8 Jan 2018.